-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | None |
| Sector | Healthcare |
| Industry | Biotechnology |
| Beta | nan |
|---|---|
| Target Price | nan |
| Dividend Yield | nan% |
| PE Ratio | nan |
| Market Cap | None |
ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for IMA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025